Longbow Starts C.R. Bard (BCR) at Neutral
More News related to BCR
- Morgan Keegan Starts BDX, HAE, BCR, MASI, COO at Outperform, BAX, HRC, COV, TFX, ISRG at Market Perform
- Bard to Host December 2009 Investor Conference
- CR Bard (BCR) Tops Q3 EPS by 3c
- Bard Announces Third Quarter Results
- Barclays Starts Stocks in Medical Equipment Group: EW, COV, MDT, ZMH at Overweight, SYK, BCR at Underweight
More News related to New Coverage
- Dahlman Rose Initiates Coverage on Independent Oil & Gas Stocks
- Sandler O'Neill Initiates Coverage on AON Corp. (AON) with a Hold
- Ameriprise Financial Initiates Coverage on Janus Capital (JNS) with a Buy
- BGB Securities Initiates Coverage on International Flavors & Fragrances (IFF) with a Buy
- Barrington Research Initiates Coverage on Masimo (MASI) with an Outperform
Longbow Research initiates coverage on C.R. Bard (NYSE: BCR) with a Neutral rating.
C. R. Bard, Inc. and its subsidiaries engage in the design, manufacture, packaging, distribution, and sale of medical, surgical, diagnostic, and patient care devices worldwide.
Related Categories
New CoverageStocks Mentioned
+0.17Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
